Compare Flagstar Bank NA (FLG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs State Street SPDR S&P Biotech ETF — how do they compare? Flagstar Bank NA trades at $11.32 (market cap $4.71B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.1× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.35% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 22 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| FLG | XBI | |
|---|---|---|
Market Cap | $4.71B | $10.11B |
Volume | 7,410,589 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $15.36 | $169.55 |
52-Week Low | $10.72 | $104.99 |
Typical Hold Time | 22 Days | 38 Days |
Enterprise Value | $15.25B | — |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.35, up 0.44% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 378.33 but trades below book value at P/B of 0.62. Recent Q2 2026 earnings missed expectations, though the company announced a $250 million share repurchase program and maintains a dividend. Analyst consensus remains bullish with a $17.07 price target.
FLG presents a turnaround opportunity with improving profitability from 2025 losses to 2026 projected net income of $48 million. Key risks include volatile cash flows and competitive banking pressures. The stock's discount to book value and strong analyst support suggest potential upside if execution improves.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
